文献速递流行病学与生物统计新药、器械与细胞基因治疗研发基础与转化研究

化脓性汗腺炎:诊断与治疗进展

Hidradenitis Suppurativa: Advances in Diagnosis and Treatment.
PubMed 文献 · JAMA · 2017-01-01

本文综述化脓性汗腺炎的诊断、流行病学与治疗,重点纳入2011年9月1日至2017年5月1日发表的文献。诊断依据皮损形态、部位及进展(6个月内2次复发或慢性/持续皮损≥3个月)。患病率0.05%至4.10%,全因死亡率升高(发生率比1.35 [95%CI, 1.15-1.59]),多种药物与手术技术可选。

要点

  • 诊断依据皮损形态、部位及进展,6个月内2次复发或持续≥3个月。
  • 患病率0.05%至4.10%,全因死亡率升高(发生率比1.35 [95%CI, 1.15-1.59])。
  • 克林霉素联合利福平或厄他培南后联合利福平、莫西沙星、甲硝唑6个月有效。

核心结论

  • 化脓性汗腺炎比既往认识更常见,可采用多种药物与手术技术治疗。
  • 对于腋窝、腹股沟、会阴及乳褶区域的结节性皮损或窦道,应考虑本病鉴别诊断。

研究设计与样本

  • 文献检索PubMed、MEDLINE(MeSH)和EMBASE,纳入2011年9月1日至2017年5月1日发表的近期治疗研究。
  • 排除综述、指南、会议摘要及患者数少于10的研究;并通过百度、必应、谷歌和Qwant浏览器检索指南。

主要发现

  • 诊断依据皮损形态(结节、脓肿、隧道、瘢痕)、部位(腋窝、乳下褶、腹股沟、生殖器周围或会阴)及进展(6个月内2次复发或慢性/持续皮损≥3个月)。
  • 流行病学分析显示患病率为0.05%至4.10%,全因死亡率升高(发生率比1.35 [95%CI, 1.15-1.59])。
  • 患者可能有显著合并症(如肥胖、代谢综合征、糖尿病和关节炎)。
  • 克林霉素联合利福平,或厄他培南后联合利福平、莫西沙星和甲硝唑治疗6个月有效。
  • 阿达木单抗对相当比例患者有效;IL-1和IL-12受体β1亚基(Rb1)抗体也可能有用。

关键数值与推荐

  • 诊断标准:6个月内2次复发或慢性/持续皮损≥3个月。
  • 患病率0.05%至4.10%。
  • 全因死亡率发生率比1.35(95%CI, 1.15-1.59)。
  • 克林霉素联合利福平或厄他培南后联合利福平、莫西沙星和甲硝唑治疗6个月。

临床怎么用

  • 在腋窝、腹股沟、会阴及乳褶区域的结节性皮损或窦道鉴别诊断中考虑化脓性汗腺炎。
  • 根据皮损形态、部位及进展标准进行诊断。
  • 抗生素联合方案治疗6个月有效。
  • 阿达木单抗对相当比例患者有效。
  • 保留组织的手术技术和二氧化碳激光治疗可用,但证据有限。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hidradenitis suppurativa (HS) is relatively common, with the prevalence of 0.05% to 4.10%, yet many patients receive inadequate treatment. OBJECTIVE: To review the diagnosis, epidemiology, and treatment of HS with an emphasis on advances in the last 5 years. EVIDENCE REVIEW: A literature search was conducted using PubMed, MEDLINE (Medical Subject Headings [MeSH]), and EMBASE to include recently published treatment studies (searched from September 1, 2011, to May 1, 2017). Reviews, guidelines, conference abstracts, and studies with less than 10 patients were excluded. Furthermore, internet searches for guidelines on hidradenitis suppurativa using Baidu, Bing, Google, and Qwant browsers were performed. FINDINGS: The diagnosis of HS is made by lesion morphology (nodules, abscesses, tunnels, and scars), location (axillae, inframammary folds, groin, perigenital, or perineal), and lesion progression (2 recurrences within 6 months or chronic or persistent lesions for ≥3 months). HS is more common than was previously thought based on epidemiological analysis (0.05%-4.10%). Disability from HS can be significant. Patients with HS may have significant comorbidities (eg, obesity, metabolic syndrome, diabetes, and arthritis) and increased all-cause mortality (incidence rate ratio, 1.35 [95% CI, 1.15-1.59]). Antibiotic treatment with combinations of clindamycin and rifampicin, or ertapenem followed by combination rifampicin, moxifloxacin, and metronidazole for 6 months is effective. Adalimumab is effective in a significant proportion of patients and treatment with IL-1 and IL-12 receptor subunit beta 1 (Rb1) antibodies may also be useful. Tissue-sparing surgical techniques and carbon dioxide laser treatments also are available, but the evidence on clinical outcomes with these approaches is limited. CONCLUSIONS AND RELEVANCE: Hidradenitis suppurativa is more common than previously thought and may be treated by an array of pharmacological and surgical techniques. Hidradenitis suppurativa should be considered in the differential diagnosis of nodular lesions or sinus tracts present in the axillae, groin, perineal, and mammillary fold regions.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Saunte DML, Jemec GBE. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA. 2017. PMID: 29183082. doi:10.1001/jama.2017.16691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。